Lp(a) and CVD risk & clinical tests to measure Lp(a)
This video clip is from episode #210 – Lp(a) and its impact on heart disease with Benoît Arsenault, Ph.D., originally…
Peter’s approach to managing patients with high Lp(a)
This video is a clip from episode #210 – Lp(a) and its impact on heart disease with Benoît Arsenault, Ph.D.,…
#210 – Lp(a) and its impact on heart disease | Benoît Arsenault, Ph.D.
“I think we should advise people to measure Lp(a); that would be a gigantic step.” —Benoît Arsenault
#138 – Lauren Miller Rogen and Richard Isaacson, M.D.: Alzheimer’s disease prevention—patient and doctor perspectives
“Believe it or not, there are 46 million Americans with Alzheimer’s disease in their brain right now, but no symptoms.” — Richard Isaacson
#129 – Tom Dayspring, M.D.: The latest insights into cardiovascular disease and lipidology
“Atherogenic lipoproteins are really the issue behind clinical atherosclerotic vascular disease. … The data has just become so overwhelming.” —Tom Dayspring
#23 – Tom Dayspring, M.D., FACP, FNLA – Part IV of V: statins, ezetimibe, PCSK9 inhibitors, niacin, cholesterol and the brain
“This is what it ultimately comes down to – and it’s the way you practice – you’ve got to individualize everything.” –Tom Dayspring
Narrative glossary: lipids
A companion post for the podcast episodes with Thomas Dayspring, M.D., FACP, FNLA (October 15-19, 2018).
#03 – Ron Krauss, M.D.: a deep dive into heart disease
“Anybody interested in this field should probably understand the origins.” —Ron Krauss
Comedy plus time…
So much of this doc really spoke to me, but two things, in particular, stood out.